Publication: A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients
Issued Date
2001-06-01
Resource Type
ISSN
15254135
Other identifier(s)
2-s2.0-0035363844
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Acquired Immune Deficiency Syndromes. Vol.27, No.2 (2001), 116-123
Suggested Citation
Chaiwat Ungsedhapand, Eugene D.M.B. Kroon, Surapol Suwanagool, Kiat Ruxrungtham, Nongluk Yimsuan, Areerat Sonjai, Sasiwimol Ubolyam, Supranee Buranapraditkun, Surapee Tiengrim, Nadine Pakker, Chaiyos Kunanusont, Joep M.A. Lange, David A. Cooper, Praphan Phanuphak A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndromes. Vol.27, No.2 (2001), 116-123. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26783
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients
Abstract
Objective: To assess the efficacy and tolerability of a triple nucleoside reverse transcriptase inhibitor combination of zidovudine, lamivudine, and didanosine therapy. Design: A randomized open-label trial. Patients: Antiretroviral-naive HIV-infected patients with CD4+cell counts of 100 to 500 cells/μl. Methods: A total of 106 patients were randomly assigned to 300 mg of zidovudine (200 mg for body weight <60 kg) twice daily plus 150 mg of lamivudine twice daily plus 200 mg of didanosine (125 mg for body weight <60 kg) twice daily (n = 53) or to zidovudine plus lamivudine (n = 53) for 48 weeks. Main Outcome Measures: Degree and duration of reduction of HIV-1 RNA load and increase in CD4+cell counts from baseline and development of drug-related toxicities. Results: At 48 weeks, triple drug therapy showed greater declines in plasma HIV-RNA levels from the beginning of treatment than double drug therapy (1.86 vs. 1.15 log10copies/ml, respectively; p < .001). The proportions of patients with HIV-RNA <50 copies/ml in an intention-to-treat analysis were 54.7% (29 of 53 patients) and 11.3% (6 of 53 patients) in the triple and double drug therapy, respectively (p = .001). There was no significant difference in increase of CD4 count. Conclusion: Triple drug therapy with zidovudine, lamivudine, and didanosine was significantly more effective in inducing sustained immunologic and virologic responses than the double combination of zidovudine and lamivudine.